GlassScriptPhysician profile
Helen Moreira
NPI 1396974812
$4,962.90
in general payments reported to CMS, 2019-2025
20 companies · $976 in 2025
The $976 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.96 · 2020: $104 · 2021: $421 · 2022: $765 · 2023: $1,153 · 2024: $1,478 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,277.44 | 2022-2025 | |
| Alcon Vision LLC | $781.89 | 2021-2025 | Eysuvis, Rocklatan, Simbrinza |
| Sun Pharmaceutical Industries INC. | $553.55 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $393.70 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $335.34 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Tarsus Pharmaceuticals, INC. | $288.04 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $271.80 | 2021-2025 | Catalys System, Tecnis Iol |
| Glaukos Corporation | $260.44 | 2021-2024 | Photrexa, Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Allergan, INC. | $199.86 | 2020-2021 | |
| Oyster Point Pharma, INC. | $196.57 | 2022-2024 | Tyrvaya |
| Rayner Intraocular Lenses Limited | $102.17 | 2022-2025 | Omidria |
| Dompe US, INC. | $59.95 | 2021-2025 | Oxervate |
| Rxsight INC | $48.99 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Omeros Corporation | $43.08 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $40.53 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $30.70 | 2023-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Eyevance Pharmaceuticals LLC | $30.52 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $22.62 | 2021 | |
| Ocular Therapeutix, INC. | $13.65 | 2024 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Moreira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.